• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
ImmunoCellular Therapeutics, Ltd. - Product Pipeline Review - Q4 2010 - Product Image

ImmunoCellular Therapeutics, Ltd. - Product Pipeline Review - Q4 2010

  • ID: 1448564
  • December 2010
  • 48 pages
  • Global Markets Direct

ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “ImmunoCellular Therapeutics, Ltd. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- ImmunoCellular Therapeutics, Ltd. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ImmunoCellular Therapeutics, Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of READ MORE >



List of Tables
List of Figures
ImmunoCellular Therapeutics, Ltd. Snapshot
ImmunoCellular Therapeutics, Ltd. Overview
Key Information
Key Facts
ImmunoCellular Therapeutics, Ltd. – Research and Development Overview
Key Therapeutic Areas
ImmunoCellular Therapeutics, Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
ImmunoCellular Therapeutics, Ltd. – Pipeline Products Glance
ImmunoCellular Therapeutics, Ltd. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
ImmunoCellular Therapeutics, Ltd.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
ImmunoCellular Therapeutics, Ltd. – Drug Profiles
ICT-107
Product Description
Mechanism of Action
R&D Progress
ICT-037
Product Description
Mechanism of Action
R&D Progress
ICT-109
Product Description
Mechanism of Action
R&D Progress
ICT-111
Product Description
Mechanism of Action
R&D Progress
ICT-121
Product Description
Mechanism of Action
R&D Progress
ICT-69
Product Description
Mechanism of Action
R&D Progress
ImmunoCellular Therapeutics, Ltd. – Pipeline Analysis
ImmunoCellular Therapeutics, Ltd. – Pipeline Products by Therapeutic Class
ImmunoCellular Therapeutics, Ltd. Pipeline Products By Target
ImmunoCellular Therapeutics, Ltd. – Pipeline Products by Molecule Type
ImmunoCellular Therapeutics, Ltd. – Recent Pipeline Updates
ImmunoCellular Therapeutics, Ltd. – Company Statement
ImmunoCellular Therapeutics, Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 13, 2010: ImmunoCellular Optimizes New Manufacturing Method For Cancer Vaccine
Oct 05, 2010: ImmunoCellular Therapeutics To Present Clinical Data For ICT-107 At World Stem Cell Summit
Sep 16, 2010: ImmunoCellular Therapeutics Selects Averion To Conduct Phase II Glioblastoma Study
Sep 08, 2010: ImmunoCellular Reports Phase I Study Data Of ICT-107 In Treatment Of Glioblastoma Multiforme
Jun 11, 2010: ImmunoCellular Receives Orphan Drug Status For ICT-107
Jun 02, 2010: ImmunoCellular's ICT-107 Demonstrates 80% Survival For Two Years In Phase I Study Of Newly Diagnosed Glioblastoma Patients
May 21, 2010: ICT To Present Clinical Results From ICT-107 At 46th Annual Meeting Of ASCO
May 03, 2010: ImmunoCellular Files Orphan Drug Application For ICT-107
May 03, 2010: ImmunoCellular Files Orphan Drug Application For ICT-107
May 03, 2010: ImmunoCellular Files Orphan Drug Application For ICT-107
Financial Deals Landscape
ImmunoCellular Therapeutics, Ltd., Deals Volume Summary, 2004 to YTD 2010
ImmunoCellular Therapeutics, Ltd., Deals Summary By Region, 2004 to YTD 2010
ImmunoCellular Therapeutics, Ltd., Deals Summary, 2004 to YTD 2010
ImmunoCellular Therapeutics, Ltd. Detailed Deal Summary
Asset Purchase
ImmunoCellular Acquires Molecular Antibody Technology From Molecular Discoveries
Equity Offering
ImmunoCellular Therapeutics Completes Private Placement Of $4 Million
ImmunoCellular Therapeutics Enters Into A Development Agreement with Formatech
ImmunoCellular Therapeutics Enters Into An Agreement With Formatech
ImmunoCellular Therapeutics Enters Into Research Agreement With Antitope
ImmunoCellular Therapeutics Enters Into Research Agreement With George Mason University
Licensing Agreements
ImmunoCellular Therapeutics Enters Into Licensing Agreement With Cedars-Sinai Medical
ImmunoCellular Therapeutics Enters Into Licensing Agreement With Cedars-Sinai
ImmunoCellular Therapeutics Enters Into Option Agreement With Roche
ImmunoCellular Therapeutics Enters Into Option Licensing Agreement With M. D. Anderson Cancer Center
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS